Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial

Lancet

Volumn 356, Issue 9247, 2000, Pages 2037-2044

  Tcheng, James E ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PYRIDINE DERIVATIVE; TICLOPIDINE;

ARTICLE; BLEEDING; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0034676781     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)03400-0     Document Type: Article

References (28)

1. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty: The EPIC Investigation
2. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
3. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study
4. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II
5. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty: Randomised efficacy study of Tirofiban for outcomes and restenosis
6. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade: Evaluation of Platelet IIb/IIIa Inhibitor for Stenting
7. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention: Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication
8. Design of potent and specific integrin antagonists with high specificity for glycoprotein IIb/IIIa
9. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention
10. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention
11. Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: Enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate
12. Pharmacodynamic study of F(ab′)2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris
13. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high risk angioplasty
14. Platelet glycoprotein IIb/IIIa receptor blockade with high-dose Integrilin™ in coronary intervention: Results of the PRIDE study
15. Eptifibatide pharmacokinetic-pharmacodynamic relationship in coronary angioplasty patients: Results of the PRIDE study
16. Design and methodology of the ESPRIT trial: Evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention
17. Thrombolysis in myocardial infarction (TIMI) trial - Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
18. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy
19. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
20. Stenting for ischemic heart disease
21. Improved clinical outcome after widespread use of coronary-artery stenting in Canada
22. Myonecrosis afte revascularization procedures
23. The myth of the myocardial 'infarctlet' during percutaneous coronary revascularization procedures
24. Ticlopidine pretreatment prior to stenting is associated with a substantial decrease in complications: Data from the EPISTENT trial
25. Current use of IIb/IIIa receptor antagonists during coronary intervention: The NHLBI 1997-1998 dynamic registry
26. Economic issues in glycoprotein IIb/IIIa receptor therapy
27. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial
28. Acute profound thrombocytopenia after c7E3 Fab (Abciximab) therapy